Innovent Biologics (HKG:1801) recorded a total product revenue of 2 billion yuan or more in the fourth quarter of 2024, up at least 25% from a year prior, a Thursday bourse filing said.
In full-year 2024, product revenue grew by at least 40% to 8.2 billion yuan.
The drug company attributed the rise in revenue mainly to its leading position in the oncology niche, fast growth of major products, and the strong ramp-up momentum of new products.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.